Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

the ECZTRA 1 and ECZTRA 2 study investigators

Research output: Contribution to journal › Article › peer-review

289 Scopus citations

Fingerprint

Dive into the research topics of 'Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*'. Together they form a unique fingerprint.

Medicine & Life Sciences